The economic cost of senile dementia in the United States, 1985
- PMID: 3124195
- PMCID: PMC1477951
The economic cost of senile dementia in the United States, 1985
Abstract
Senile dementia is a progressive and irreversible decline of mental functions. The symptoms are mental confusion, memory loss, disorientation, cognitive decline, and inappropriate social behavior. It is one of the most common, costly, and distressful diseases among the elderly in the United States. Information on the economic costs of senile dementia is essential for determining research priorities and the allocation of resources to support aging and medical research. Economic consequences, such as direct medical and nonmedical expenditures by patients' families and the amount of time by third parties in caring for patients with senile dementia, are substantial. However, little systematic accounting to estimate these consequences has been undertaken. This paper attempts to estimate various costs associated with the care of senile dementia, based on available secondary data. We have used the direct cost and indirect cost approach and avoided double counting to identify the additional economic costs due to senile dementia. The total, direct national cost of senile dementia is $13.26 billion, which includes $6.36 billion of medical care costs, $2.56 billion of nursing home care costs, and $4.34 billion of social agency service costs. The indirect cost for community home care alone is $31.46 billion, more than twice the total direct costs. The costs of premature death and loss of productivity due to senile dementia are about $43.17 billion. Although most of the indirect costs were imputed from the value of housekeeping or productivity loss, the magnitude of indirect costs reflects the serious consequences and burden on society's resources of this disease.
Similar articles
-
Net economic costs of dementia in Canada.CMAJ. 1994 Nov 15;151(10):1457-64. CMAJ. 1994. PMID: 7954140 Free PMC article.
-
The economic impact of dementia in Belgium: results of the National Dementia Economic Study (NADES).Acta Neurol Belg. 2002 Sep;102(3):104-13. Acta Neurol Belg. 2002. PMID: 12400248
-
The costs of dementia from the societal perspective: is care provided in the community really cheaper than nursing home care?J Am Med Dir Assoc. 2014 Feb;15(2):117-26. doi: 10.1016/j.jamda.2013.10.003. Epub 2013 Dec 8. J Am Med Dir Assoc. 2014. PMID: 24321877
-
Economic costs of diabetes in the U.S. In 2007.Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review.
-
Economic considerations in Alzheimer's disease.Pharmacotherapy. 1998 Mar-Apr;18(2 Pt 2):68-73; discussion 79-82. Pharmacotherapy. 1998. PMID: 9543467 Review.
Cited by
-
Long-term care eligibility criteria for people with Alzheimer's disease.Health Care Financ Rev. 1999 Summer;20(4):67-85. Health Care Financ Rev. 1999. PMID: 11482125 Free PMC article.
-
[Psychiatry in transitions of the public health system].Nervenarzt. 2004 Nov;75(11):1049-52. doi: 10.1007/s00115-004-1807-3. Nervenarzt. 2004. PMID: 15480531 German. No abstract available.
-
The US economic and social costs of Alzheimer's disease revisited.Am J Public Health. 1994 Aug;84(8):1261-4. doi: 10.2105/ajph.84.8.1261. Am J Public Health. 1994. PMID: 8059882 Free PMC article.
-
Direct costs of dementia in nursing homes.Front Aging Neurosci. 2015 Jul 28;7:146. doi: 10.3389/fnagi.2015.00146. eCollection 2015. Front Aging Neurosci. 2015. PMID: 26283959 Free PMC article.
-
Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.Drugs Aging. 2001;18(7):527-50. doi: 10.2165/00002512-200118070-00006. Drugs Aging. 2001. PMID: 11482746 Review.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical